Bioanalytical Testing Services Market Benefits From Precision Medicine

The global bioanalytical testing services market size was valued at USD 4.80 billion in 2024 and is projected to reach USD 11.24 billion by 2033, expanding at a CAGR of 9.93% from 2025 to 2033. Market growth is primarily driven by rising drug development activities, increasing drug approval volumes, growing therapeutic complexity, and the accelerated shift toward outsourcing specialized testing services.

Key Market Trends & Insights

  • North America accounted for the largest revenue share at 47.40% in 2024.
  • The U.S. market contributed the highest share within the region.
  • By molecule type, small molecules dominated with 55.67% revenue share in 2024.
  • By test type, the bioequivalence segment emerged as the leading category in 2024.

Market Size & Forecast

  • 2024 Market Size: USD 4.80 Billion
  • 2033 Market Size: USD 11.24 Billion
  • CAGR (2025–2033): 9.93%
  • North America: Largest regional market
  • Asia-Pacific: Fastest-growing region

The emergence of advanced therapeutic modalities—including biologics, cell therapies, and gene therapies—has increased the demand for highly specialized and sensitive bioanalytical testing solutions. Continuous advancements such as high-throughput screening (HTS), LC-MS, and next-generation sequencing (NGS) have significantly improved data accuracy, efficiency, and analytical depth. The adoption of automation and AI in bioanalytical workflows has further enhanced productivity by reducing manual errors and accelerating test cycles.

Rising regulatory scrutiny across pharmacokinetics, pharmacodynamics, and bioequivalence studies is also contributing to higher outsourcing levels. Regulatory bodies such as the U.S. FDA and EMA increasingly emphasize stringent testing protocols, strengthening the need for validated, precise, and reliable bioanalytical methods—driving companies to partner with experienced CROs.

Order a free sample PDF of the Bioanalytical Testing Services Market Intelligence Study, published by Grand View Research.

Key Bioanalytical Testing Services Company Insights

Leading industry players are expanding analytical capabilities, investing in advanced instrumentation, and forming strategic collaborations to meet the growing demand for complex assay development and advanced large-molecule testing. For example, in August 2024, SGS launched specialized bioanalytical testing services in Hudson, New Hampshire, offering advanced capabilities for both pharmaceutical and biopharmaceutical clients.

Leading Companies in the Bioanalytical Testing Services Market

  • Thermo Fisher Scientific Inc. (PPD, Inc.)
  • ICON Plc
  • Charles River Laboratories International
  • IQVIA
  • Syneos Health
  • SGS SA
  • Labcorp
  • Intertek Group Plc
  • Pace Analytical Services LLC

Conclusion

The bioanalytical testing services market is experiencing strong, sustained expansion driven by the rising complexity of modern therapeutics, increased R&D investments, and stringent global regulatory requirements. As pharma and biotech companies continue to outsource specialized testing, service providers are adopting advanced technologies and expanding their global footprint to meet evolving needs. The growing emphasis on precision, reliability, and accelerated drug development timelines will further reinforce the importance of bioanalytical services in the coming decade.

Explore Horizon Databook – The world’s most expansive market intelligence platform developed by Grand View Research.

Comments

Post a Comment

Popular posts from this blog

Urodynamic Equipment and Consumables Market Forecast: Anticipating Future Innovations

  The global urodynamic equipment and consumables market size is expected to reach USD 449.2 million in 2030 and is projected to grow at a CAGR of 5.7% from 2024 to 2030. This market is anticipated to grow at an unprecedented rate owing to growing geriatric population that exhibits greater vulnerability to urological dysfunctions. In addition, unprecedented upsurge in prevalence of bladder cancer poses high clinical urgency to adopt highly efficient diagnostics, which thereby broadens future growth prospects. In 2017, as per the American Cancer Society, bladder cancer accounted for 5.0% of all cancers in the U.S. The market is also driven by global increase in obesity. As per the Centers for Disease Control and Prevention, approximately 36.0% of adult population is obese. According to a research published in NCBI, obesity has increased the risk of developing various urological conditions, such as prostate cancer, nephrolithiasis, hypogonadism, and urinary tract infections. Furtherm...
Read more

Mobile Device Management Market Thrives with Growth in Cloud-Based Solutions

  According to a recent report by Grand View Research, Inc., the global   mobile device management (MDM) market   is projected to reach USD 28.37 billion by 2030, expanding at a CAGR of 24.5% from 2025 to 2030. This growth is primarily attributed to the increasing use of mobile devices in the workplace and the growing need to manage and secure them effectively. As smartphones, tablets, and other mobile devices become more prevalent, employees are increasingly using their personal devices for work—an approach known as Bring Your Own Device (BYOD). This trend is contributing to the rising number of mobile devices requiring centralized oversight and protection. MDM solutions offer organizations a unified platform to oversee and secure mobile devices, enabling functions such as security policy enforcement, device usage monitoring, and remote data wiping in cases of loss or theft. As companies continue to implement BYOD strategies or issue corporate devices to employees, deman...
Read more

U.S. Interventional Oncology Market Boosted by Aging Population

  The   U.S. interventional oncology market   size was estimated at USD 998.4 million in 2024 and is projected to reach USD 1,597 million by 2030, expanding at a CAGR of 8.17% from 2025 to 2030. This market growth is primarily driven by the increasing prevalence of cancer, continuous technological advancements in minimally invasive treatments, expanding investments in interventional oncology, and the aging population across the U.S. A major contributing factor is the rising incidence of cancer in the country. According to the American Cancer Society, approximately 2,041,910 new cancer cases are expected to be diagnosed in the U.S. in 2025, with 618,120 projected cancer-related deaths. As conventional therapies like chemotherapy and radiation often lead to significant side effects, minimally invasive techniques such as radiofrequency ablation and microwave ablation are becoming more popular. These procedures target tumors precisely while minimizing harm to surrounding tiss...
Read more